BiotechTube

Briquilimab

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Spontaneous Urticaria

Conditions

Chronic Spontaneous Urticaria

Trial Timeline

Nov 29, 2023 → Oct 31, 2026

NCT ID
NCT06162728

About Briquilimab

Briquilimab is a phase 1/2 stage product being developed by Jasper Therapeutics for Chronic Spontaneous Urticaria. The current trial status is active. This product is registered under clinical trial identifier NCT06162728. Target conditions include Chronic Spontaneous Urticaria.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (4)

NCT IDPhaseStatus
NCT06736262Phase 2Active
NCT06592768Phase 1Terminated
NCT06353971Phase 1/2Terminated
NCT06162728Phase 1/2Active

Competing Products

20 competing products in Chronic Spontaneous Urticaria

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Jasper Therapeutics

BriquilimabPhase 2
44
BriquilimabPhase 1/2
33
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1/2
33
JSP191Phase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1
25